GPX4 has thus arisen as a potential cancer drug target, and several small molecules that were originally identified as modulators of ferroptosis in cancer cells have now been recognized as inhibitors of GPX4 and may serve as starting points towards future small-molecule drugs for GPX4, including RSL3 (Yang & Stockwell, 2008 ▸), ML162 and ML210 (Weïwer et al., 2012 ▸) (Fig. 1 ▸). The gene discussed is GPX4; the disease is cancer.